Extracellular ATP (adenosine triphosphate) and adenosine have immunoregulatory roles during inflammation. Elevated extracellular ATP is known to exacerbate graft-versushost disease (GvHD) and pharmacologic activation of the adenosine A 2A receptor is protective. However, the role of endogenous adenosine is unknown. We used gene targeted mice and a pharmacologic inhibitor to test the role of adenosine generated by CD73/ecto-5'-nucleotidase in GvHD. In allogeneic transplants, both donor and recipient CD73 were protective, with recipient CD73 playing the dominant role. CD73 deficiency led to enhanced T cell expansion and IFNγ and IL-6 production and the migratory capacity of cd73 -/-T cells in vitro was increased. However, the number of regulatory T cells and expression of co-stimulatory molecules on antigen presenting cells were unchanged. A 2A receptor deficiency led to increased numbers of allogeneic T cells suggesting that signaling through the A 2A receptor via CD73-generated adenosine is a significant part of the mechanism by which CD73 limits the severity of GvHD.
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Pharmacologic blockade of CD73 also enhanced graft-versus-tumor activity. These data have clinical implications, as both the severity of GvHD and the strength of an alloimmune anti-tumor response could be manipulated by enhancing or blocking CD73 activity or adenosine receptor signaling depending upon the clinical indication.
Introduction
Patients with hematologic malignancies that are refractory to conventional chemotherapy have a chance of cure by allogeneic hematopoietic stem cell transplantation (allo-HCT) 1 .
However, the success of this treatment is limited by graft-versus-host disease (GvHD) 2 .
We have recently shown that extracellular adenosine triphosphate (ATP), which is released from dying or stressed cells and serves as an endogenous danger signal to evoke systemic inflammatory responses, enhances GvHD by activation of the purinergic receptor P2X 7 R 3, 4 . The abundance of extracellular ATP is regulated by ectonucleotidases such as CD39 which dephosphorylates ATP to ADP and AMP.
Extracellular AMP is dephosphorylated to adenosine via the action of CD73, a glycosyl phosphatidylinositol-anchored glycoprotein with ecto-5'-nucleotidase enzyme activity [5] [6] [7] .
CD73 is expressed on many cell types including subsets of T lymphocytes, endothelial cells and epithelial cells 7, 8 . It is also present as a secreted form lacking a glycosyl also required for cardioprotection as a result of ischemic preconditioning 21 . Extracellular adenosine inhibits platelet activation and leukocyte adhesion to the vascular endothelium 22 and limits lymphocyte migration into draining lymph nodes after an inflammatory stimulus via a CD73-dependent mechanism 23 . CD73 also inhibits antitumor immune responses [24] [25] [26] [27] .
There are a number of additional model systems where AR signaling has been shown to play a role in immune regulation, but the importance of CD73 in producing adenosine to trigger the receptors has not been studied. For example, immune regulation via the activation of A 2A and/or A 2B AR in T cells and dendritic cells (DCs) has been documented 28, 29 . In addition, a specific A 2A AR agonist has been shown to inhibit allogeneic immune activation in vitro via actions on both T cells and antigen presenting cells and to delay skin allograft rejection in vivo 14 . Another A 2A AR agonist was shown to attenuate acute GvHD following allo-HCT 13 . These findings support the concept that extracellular adenosine counteracts ATP-triggered immune activation as a negative feedback mechanism to prevent uncontrolled tissue destruction due to excessive inflammation.
The goal of this study was to delineate the role of CD73 in acute GvHD and graftversus-leukemia (GvL) responses. We employed in vivo bioluminescence imaging (BLI)
based T cell and tumor cell tracking methodologies 30 in combination with mice genetically deficient for CD73. Our data clearly indicate that CD73 plays a tolerogenic role after allo-HCT and has an impact on GvL effects that could be exploited in the clinical situation by using a CD73 inhibitor. 
BMT model and induction of GvHD
Bone marrow transplantation (BMT) experiments were performed as previously described 32 . Briefly, in Freiburg, recipients received myeloablative total body irradiation (10 Gy in two equal split doses, four hours apart), followed by intravenous injection of 5 x 10 6 bone marrow (BM) cells. For induction of acute GvHD, CD4 + and CD8 + splenic T cells were enriched with CD4/CD8 MACS Micro Beads and LS columns (Miltenyi Biotec).
The number of injected T cells varied depending on the transplant model: C57BL/6 → BALB/c (3 x 10 5 T cells), FVB/N → C57BL/6 (1 x 10 6 T cells) and BALB/c → C57BL/6 (2 x 10 5 T cells). At OMRF, C57BL/6 mice received myeloablative doses of total body irradiation (13 Gy in two equal split doses, three hours apart) followed by intravenous injection of 5 x 10 6 BM cells and 10-20 x 10 6 splenocytes from BALB/c mice. After BMT, Baytril® was given in the drinking water at 0.5 mg/ml for three to four weeks to prevent infection. Any mice with weight loss >30% of the original body weight or with clinical
GvHD scores 33 >6 were euthanized. GvHD was also induced by transplantation of C57BL/6 cells into BALB/c mice using 10 Gy in two equal split doses, three hours apart, 5 x 10 6 BM cells plus 5-10 x 10 6 C57BL/6 splenocytes, and loss of body weight >35% as a criterion for euthanasia.
Histopathology scoring of acute GvHD
Sections of liver and small and large intestine collected 10 days after BMT were stained with hematoxylin/eosin (H&E) and scored by an experienced pathologist (U.V.G.) blinded to the treatment groups as described by Kaplan 34 . Intestinal GvHD was scored on the basis of crypt apoptosis (0, rare to none; 1, occasional apoptotic bodies per 10 crypts; 2, few apoptotic bodies per 10 crypts; 3, the majority of crypts contain an apoptotic body; 4, the majority of crypts contain >1 apoptotic body) and inflammation (0, none; 1, mild; 2, moderate; 3, severe, without ulceration; 4, severe, with ulceration). given to induce GvL. Tumor expansion was quantified by in vivo BLI.
In vivo inhibition of CD73 and antagonism of ARs
APCP (adenosine 5'-(α, β -methylene) diphosphate,
In vivo BLI
For in vivo BLI, ten minutes after intraperitoneal injection with 150 µg/g body weight luciferin (D-Luciferin 1-(4,5-dimethoxy-2-nitrophenyl) ethyl ester, Biosynth), mice were imaged using an IVIS100 charge-coupled device imaging system (Xenogen) with exposure time of 5 minutes 37 . The signal from luc + transgenic FVB/N T cells or A20 leukemia cells was quantified in photons/s/mouse. Imaging data were analyzed and quantified with Living Image 3.2 Software (Calipers).
Cytokine measurements in serum of mice with GvHD
IL-6 and IFNγ were measured in serum collected from transplant recipients 6-7 days after BMT using the Ready-Set-Go ELISA kit (eBioscience).
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Generation of BM-DC
Bone marrow-derived dendritic cells (BM-DCs) were prepared as described 38 , except that IL-4 was not added and were used on days 7 to 9 of culture.
In vitro and in vivo T cell proliferation assays
Splenic CD4 + T cells were isolated using CD4 MACS Microbeads and LS Columns 
T cell migration assay
Six hundred µL of RPMI supplemented with 2% FCS were added into the bottom of a 24-well transwell plate ± 100 ng/mL of CXCL12 (R&D Systems gel electrophoresis verified a specific single amplification product of the target genes.
In vivo CTL activity
In vivo cytotoxic T lymphocyte (CTL) assays were performed as previously described by 
Irradiation-induced DC activation
Twenty-four hours after receiving lethal irradiation, the expression of CD86 on CD11c + CD11b + B220 -C57BL/6 splenic DCs was analyzed by flow cytometry.
Competitive engraftment
Competitive engraftment assays were performed as previously described by Esplin et al. 43 BMT was compared to that of pre-injection donor cells (day 0).
Statistical analysis
Statistical analyses were performed with GraphPad Prism 4/5 Software. Data are reported as means ± SEM or SD. Kaplan-Meier survival curves were analyzed by logrank tests. Comparisons among groups in other experiments were performed with a twotailed unpaired Student t test. P-values <0.05 were considered to be statistically significant.
Results

CD73 deficiency leads to enhanced GvHD severity
To GvHD. To verify that the effects were due to CD73's ecto-5'-nucleotidase enzyme activity, allo-HCT recipients were treated with a CD73 enzyme inhibitor (APCP).
Pharmacologic inhibition enhanced GvHD related mortality ( Figure 1F , p=0.0022)
suggesting that CD73-generated adenosine plays a central role in tolerance after allo-HCT. These data indicate that the enzymatic function of CD73 is critical to reduce the severity of GvHD. Other postulated functions of CD73, such as signal transduction 7 or cell adhesion 44 , would not be impacted by this pharmacological intervention.
As expected, the increased mortality observed in cd73 -/-recipients of allogeneic BM and T cells was accompanied by histopathologic evidence of increased GvHD severity.
Histopathologic evaluation of liver, small intestine, and colon according to a previously published scoring system 34 demonstrated significantly higher scores in cd73 -/-recipients ( Figure 1G ).
CD73 deficiency increases T cell expansion following allo-HCT
The mechanism by which CD73 deficiency enhances GvHD could be due to lower 
CD73 deficiency leads to increased proinflammatory IFNγ and IL-6 serum levels and enhances T cell migration
Following allo-HCT, the proinflammatory cytokines IFNγ and IL-6 contribute to GvHD development. Comparison of allo-HCT recipients (BALB/c → C57BL/6) revealed 4-to 5-fold higher IFNγ and IL-6 serum levels collected 6 to 7 days after transplantation when donor and recipient were CD73-deficient (p<0.05, Figure 3A) . Besides proinflammatory cytokines, migration of T cells towards secondary lymphoid organs and GvHD target tissues is required for the development of GvHD. We observed enhanced T cell migration towards a chemotactic CXCL12 gradient in vitro when the T cells were derived from cd73 -/-mice as compared to WT mice (p<0.05, Figure 3B ). As CXCR4, the receptor for CXCL12, was abundantly expressed on both CD4 + and CD8 + T cells during GvHD ( Figure 3C ), these findings suggest that increased proinflammatory cytokine production and T cell migration may contribute to the enhanced allo-immune response in the absence of CD73.
The consequences of CD73 deficiency are not via Tregs or costimulatory molecule expression
Based on the role of Foxp3 + regulatory T cells (Tregs) in protection from GvHD 31,32 , we next evaluated whether this cell population was relevant for the observed enhanced GvHD severity in CD73-deficient mice. However, we found no differences in the numbers of donor Tregs in spleens or colons of recipients of cd73 +/+ vs. cd73 -/-allo-HCT transplants ( Figure 4A ). We next compared the ability of WT vs. cd73 -/-DC from C57BL/6 mice to stimulate the proliferation of allogeneic WT BALB/C T cells in culture.
( Figure 4B ). No differences in T cell proliferation were seen at two different DC:T cell ratios, suggesting that WT and cd73 -/-DC exhibit similar intrinsic allostimulatory activity in vitro. As previous studies had shown the relevance of the costimulatory molecules Figure 4C ).
Cytotoxicity against host cells and GvL activity of donor T cells are enhanced when CD73 is deficient or inhibited
To evaluate the cytotoxic activity of donor T cells against allogeneic targets in vivo, we One mechanism by which CD73 deficiency could lead to increased severity of GvHD is via reduced AR signaling. To test this hypothesis, WT mice underwent allogeneic BMT and were then treated with the general AR antagonist, caffeine at a dose (10 mg/kg, intraperitoneally) previously shown to inhibit AR signaling 35 . As shown in Figure 6A , mortality was increased (p=0.0015) by chronic treatment with caffeine, indicating that the severity of GvHD was exacerbated and suggesting that endogenous AR signaling limits the extent of GvHD.
To gain insight into which AR(s) might be involved, the expression of all four ARs was evaluated by qRT-PCR in CD4 + and CD8 + T cells isolated from control mice and mice experiencing GvHD. The A 1 , A 2B , and A 3 ARs were each expressed at low levels and their expression did not change in a reproducible fashion during GvHD (Table 1 ). In contrast, the level of A 2A AR expression was up-regulated 3-to 5-fold on both CD4 + and CD8 + T cells during GvHD (Table 1) in the production of extracellular adenosine for A 2A AR signaling.
Adenosine receptors were also expressed in GvHD target tissues such as the liver, small intestine, and colon ( Table 1 ). The most significant changes after the induction of GvHD were a 2.8-fold increase in the A 1 AR in the colon and a 2.8-fold increase in the A 2B AR in the small intestine. As much less is known about the consequences of adenosine receptor signaling in these tissues, additional experimentation will be required to determine whether they play a role in the less severe GvHD observed in wild type compared to CD73-deficient animals.
For
Discussion
Tissue damage is recognized by the immune system via the release of endogenous molecules derived from the cytosol or mitochondria of stressed cells such as damageassociated molecular patterns 45 showing a protective role of CD73 for organ graft survival 16 . In light of these data from solid organ transplantation and our data, CD73 appears to act as a rescue mechanism along with CD39 to protect cells from the proinflammatory effects of extracellular ATP released as a consequence of tissue damage. The anti-inflammatory action of CD73 after allo-HCT is likely based upon its ability to generate adenosine, as treatment of mice with an inhibitor of CD73's ecto-5'-nucleotidase enzyme activity also increased the For The results are combined from 2 independent experiments (n=20/group For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
